SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Hikal - Quaterly Results

02 Feb 2023 Evaluate
A minor change in the total revenue was seen in the December 2022 quarter. The total revenue for the quarter stood at Rs. 5402.00 millions against Rs. 5145.30 millions during year ago period.Profit after Tax for the quarter ended December 2022 saw a decline of -41.57% from Rs. 452.00 millions to Rs. 264.10  millions.The Operating Profit of the company witnessed a decrease to 770.90 millions from 934.80 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202212 202112 % Var 202212 202112 % Var 202203 202103 % Var
Sales 5402.00 5145.30 4.99 14777.40 14403.70 2.59 19427.20 17204.40 12.92
Other Income 25.10 5.70 340.35 70.30 46.20 52.16 48.90 49.80 -1.81
PBIDT 770.90 934.80 -17.53 1740.10 2841.40 -38.76 3454.50 3278.70 5.36
Interest 130.30 71.80 81.48 351.20 231.30 51.84 312.10 362.00 -13.78
PBDT 640.60 863.00 -25.77 1388.90 2610.10 -46.79 3142.40 2916.70 7.74
Depreciation 282.70 246.80 14.55 821.80 714.40 15.03 956.70 852.40 12.24
PBT 357.90 616.20 -41.92 567.10 1895.70 -70.08 2185.70 2064.30 5.88
TAX 93.80 164.20 -42.87 144.00 498.20 -71.10 580.60 732.80 -20.77
Deferred Tax -10.50 -5.20 101.92 -13.80 -20.30 -32.02 -15.90 -62.70 -74.64
PAT 264.10 452.00 -41.57 423.10 1397.50 -69.72 1605.10 1331.50 20.55
Equity 246.60 246.60 0.00 246.60 246.60 0.00 246.60 246.60 0.00
PBIDTM(%) 14.27 18.17 -21.45 11.78 19.73 -40.31 17.78 19.06 -6.69

Hikal Share Price

192.15 3.60 (1.91%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×